Latest News
A de-aging technique offers hope for halting damage in early macular degeneration.
By unlocking the secrets of how cells communicate, this first-of-its-kind BrightFocus National Glaucoma Research-funded study could help prevent vision loss and restore sight for those living with the disease.
Sinaptica Therapeutics unveils breakthrough Phase 2 results for an experimental non-invasive treatment for Alzheimer’s disease.
Get the latest in Alzheimer’s screening and treatments.
In This Issue:
- Blocking a “Master Switch” in the Eye to Treat Glaucoma
- Growing Cells to Restore the Eye-Brain Connection
- Researcher Spotlight: Mark Prausnitz, PhD
- Treatment Options: Which One Is Right for You?
- And more!
Blue light may damage the eyes by causing unstable “free radicals” to form, which increases the risk of age-related macular degeneration. BrightFocus-funded research offers a potential way to protect the eyes from blue light.
A BrightFocus-funded scientist is investigating a novel imaging tool that could be used to find treatable blood clots in the brain and slow the progression of Alzheimer’s disease.
Students and senior Alzheimer’s researchers gathered in Chicago for an immersive workshop hosted by BrightFocus Foundation.
BrightFocus proudly supports over 200 cutting-edge research grants, fueling the global fight against Alzheimer’s disease, macular degeneration, and glaucoma.
"It's never too early in life or too late in life to reduce risk for dementia,” says Dr. Quincy Samus, a member of the Lancet Standing Commission on Dementia Prevention, Intervention, and Care. Learn more about two new ways to do so.
